Resverlogix Corp.

ApoA-I Data Presented at European Society of Cardiology Congress

    Calgary, Canada (ots/PRNewswire) -

    - Multiple Presentations Included Resverlogix Data

    - TSX Exchange Symbol: RVX

    Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased  to announce that Dr. Norman Wong presented key clinical data pertaining to  its lead compound, RVX-208, at the European Society Cardiology (ESC) 2008  Congress in Munich. The presentation titled "RVX-208 a novel small molecule  that increases apolipoprotein A-I enters into human clinical trials" was  delivered on August 31, 2008. In addition to this presentation, other  important data relating to RVX-208 from Resverlogix's extensive data  portfolio was presented by Dr. Jacques Genest of McGill University and Dr.  Stephen Nicholls of the Cleveland Clinic, at the same conference.

    "Over the past year, the scientific community has pushed to the forefront  the importance of a small molecule in the form of an oral tablet that  significantly increases ApoA-I production, HDL functionality and thereby  treats atherosclerosis cardiovascular disease," stated Dr. Jan Johansson,  Senior Vice President Medical Affairs Resverlogix. Johansson further added,  "The ESC is a well regarded scientific meeting as well as one of the largest  with an estimated 25,000 participants. We are pleased to have presented our data to this esteemed audience."

    Apolipoprotein A-I (ApoA-I), the main component of high-density lipoprotein (HDL) represent the body's natural defense system against atherosclerosis by  mediating reverse cholesterol transport, i.e. transport  of peripheral  cholesterol including that of the vessel wall to the liver for  elimination  from the body. In multiple human and animal studies over- expression or repeated infusion of ApoA-I inhibit progression and induce  regression of atherosclerosis in animals and humans.

    RVX-208, a novel small molecule drug that facilitates endogenous ApoA-I  production, is positioned as an emerging drug that holds the most promise for  the treatment of atherosclerosis. RVX-208 is designed to increase ApoA-I  production and thereby raise HDL levels thus enhancing HDL functionality to  augment reverse cholesterol transport.

    About Resverlogix Corp.

    Resverlogix Corp. is a leading biotechnology company engaged in the  development of novel therapies for important global medical markets with  significant unmet needs. The NexVas(TM) program is the Company's primary  focus which is to develop novel small molecules that enhance ApoA-I. These  vital therapies address the grievous burden of atherosclerosis and other  important diseases such as acute coronary syndrome, diabetes, Alzheimer's  disease and other vascular disorders. The Company's secondary focus is TGF- Beta Shield(TM), a program that aims to address burgeoning grievous diseases,  such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit

    This news release may contain certain forward-looking statements that  reflect the current views and/or expectations of Resverlogix Corp. with  respect to its performance, business and future events. Such statements are  subject to a number of risks, uncertainties and assumptions. Actual results  and events may vary significantly. The TSX Exchange does not accept  responsibility for the adequacy or accuracy of this news release.

    For further information: Theresa Kennedy, VP, Corporate Communications,  Resverlogix Corp., Phone: +1-604-538-7072, Email:;  Sarah Zapotichny, Manager, Investor Relations, Resverlogix Corp., Phone:  +1-403-254-9252, Email:


ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar:

For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Email:; Sarah Zapotichny, Manager, Investor
Relations, Resverlogix Corp., Phone: +1-403-254-9252, Email:

Weitere Meldungen: Resverlogix Corp.

Das könnte Sie auch interessieren: